The Patent Finder
IP

Ironshore Pharmaceuticals & Development, Inc.

First filing 2012
OverviewNotableFeesChangesFamiliesPatent listSources & methods

22 patents currently held

1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Mar 2032. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2032
Next term end
1
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 1, 2027
    The maintenance fee for Compositions for Treatment of Attention Deficit Hyperactivity Disorder (US 9,119,809) comes due Mar 1, 2027. Unpaid by Sep 1, 2027, it lapses early.
  • 1 fee due Aug 27, 2027
    The maintenance fee for Compositions for Treatment of Attention Deficit Hyperactivity Disorder (US 11,911,518) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
  • 2 fees due Sep 15 to 22, 2027 · next Sep 15

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 8,916,588Methods for Treatment of Attention Deficit Hyperactivity Disorder
In force
 · Medium confidence
In forceMedium confidence
US 8,927,010Compositions for Treatment of Attention Deficit Hyperactivity Disorder
In force
 · Medium confidence
In forceMedium confidence
US 9,023,389Compositions for Treatment of Attention Deficit Hyperactivity Disorder
In force
 · Low confidence
In forceLow confidence
US 9,028,868Methods and Compositions for Treatment of Attention Deficit Disorder
In force
 · Medium confidence
In forceMedium confidence
US 9,034,902Methods for Treatment of Attention Deficit Hyperactivity Disorder
In force
 · Low confidence
In forceLow confidence
US 9,119,809Compositions for Treatment of Attention Deficit Hyperactivity Disorder
In force
 · Medium confidence
In forceMedium confidence
US 9,283,214Compositions for Treatment of Attention Deficit Hyperactivity Disorder
In force
 · Medium confidence
In forceMedium confidence
US 9,289,394Compositions for Treatment of Attention Deficit Hyperactivity Disorder
In force
 · Medium confidence
In forceMedium confidence
US 9,498,447Compositions for Treatment of Attention Deficit Hyperactivity Disorder
In force
 · Medium confidence
In forceMedium confidence
US 9,511,032Compositions for Treatment of Attention Deficit Hyperactivity Disorder
In force
 · Medium confidence
In forceMedium confidence
10 of 22 patents shown.
Pro members see all 22.
Pro members: see all 22 patents
Also on record, not counted in the 22: 1 patent in force now held by others · 2 applications pending · 3 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
6 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
3 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited